5Biour M, Jaillon P. Drug -induced hepatic diseases. Pathol Biol Paris, 1999,47(9) :928 -937.
6Reyes H, Simon FR. Intrahepatic cholestass of pregnancy:Anestrogen-related disease. Semin Liver Dis, 1993;13(3) :289-301.
7Turktas H, Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis.Tuber Lung Dis, 1994, 75: 58-60.
8Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med,2003, 167: 809-810.
9Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf, 2001, 24: 483-490.
10Kunimoto D, Warman A, Beckon A, et al. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis, 2003, 36: 158-161.
